Immix Biopharma (IMMX) Proxy Filing summary

Executive summary

• Annual meeting scheduled for June 20, 2025, to elect eight directors and ratify the appointment of Crowe LLP as independent auditor for 2025.

• Shareholders of record as of April 22, 2025, are entitled to vote; 27,830,901 shares outstanding.

• Proxy materials are available online, and voting can be done via Internet, mail, or in person.

Voting matters and shareholder proposals

• Two proposals: election of eight directors and ratification of Crowe LLP as auditor.

• Directors are elected by plurality; auditor ratification requires a majority of votes present.

• Shareholder proposals for the 2026 meeting must be submitted by January 2, 2026, for inclusion in proxy materials.

• Advance notice and universal proxy card requirements apply for director nominations.

Board of directors and corporate governance

• Board consists of eight directors, six of whom are independent.

• CEO also serves as Chairman; lead independent director presides over meetings without the Chairman.

• Three standing committees: Audit, Compensation, and Nominating and Corporate Governance, all with independent members.

• Board and committees met regularly in 2024; all directors attended at least 75% of meetings.

• Board diversity valued but no formal diversity policy; no term limits for directors.